For many pharmaceutical conglomerates, a portfolio focused on Medicinal Cannabis products is an economic and operational challenge. However, it shows great promise. In this environment, new companies emerge to assume the role of specialized supplier of Medicinal Cannabis, with the objective of meeting the growing demand for these products.

Accompanying the “boom” of the new market, companies and startups began to mobilize efforts to market products in Brazil, still facing many technical and regulatory barriers to maintaining their businesses in the medium and long term.

With recognized expertise in regulatory affairs and structuring of new businesses, we assume the responsibility of changing this reality through CepaPharma's operating model.

If our purpose is to regenerate lives through business and competitive and efficient therapeutic products, cost optimization is a priority!

We operate with a lean and flexible structure when compared to those of the pharmaceutical industries that dominate the global scenario. This differential generates an optimized operation to meet the specific needs of the market and the segment, which guarantees products that are increasingly accessible and manufactured in Brazil.

In this business model, we contribute to the local economy, in order to add the benefits of national manufacturing and generate income, in addition to new perspectives for everyone via final products.